Navigation Links
Masimo Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/3/2009

or the fiscal year ended January 3, 2009, Masimo reported product revenues of $258.9 million, up 29.7% from $199.7 million in 2007. Including royalty revenues, Masimo's total revenues were $307.1 million for the year ended January 3, 2009, up from $256.3 million in 2007. For the year ended January 3, 2009, Masimo reported earnings of $31.9 million or $0.53 per share, including the $14.9 million tax charge related to the implementation of its new international business organization and structure. Excluding the Q4 2008 tax charge, net income would have been $46.8 million, or $0.78 per share compared to $0.60 per share in 2007. In the year ended January 3, 2009, Masimo shipped 120,100 Masimo SET and Masimo Rainbow SET pulse oximeter units, excluding handheld pulse oximeters, compared to 116,300 in 2007.

In the fourth quarter of 2008, revenues from Masimo Rainbow SET products increased to $4.7 million or 161% from $1.8 million in the same prior year quarter. For the year ended January 3, 2009, revenues from Masimo Rainbow SET products were $13.4 million, an increase of 91% compared to 2007. As a result, 2008 Masimo Rainbow SET revenues accounted for 5.2% of total product revenues up from 3.7% in 2007.

Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, "We have been fortunate that, despite the very challenging economic environment, hospitals and physicians continue to focus on the quality and efficiency of their patients' care and, as a result, continue to migrate to Masimo's gold standard SET pulse oximetry and Rainbow SET Pulse CO-Oximetry platforms. Our on-going business model, which is based on both new product innovation and a recurring revenue stream, is continuing to show resilience in this difficult worldwide economic climate."

As of January 3, 2009, cash and cash equivalents totaled $146.9 million, up from $96.7 million at December 29, 2007, including the previously announced first qu
'/>"/>

SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members
2. Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
3. Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009
4. Masimo Files Patent Infringement Suit Against Philips
5. Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care
6. Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference
7. Masimo Launches First Non-adhesive Pulse Oximetry Sensor Designed For Extremely Low Birth Weight Babies
8. Masimo Reports Second Quarter 2008 Financial Results
9. Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
10. First Nursing Facility Installation of Masimo Patient SafetyNet(TM) Goes Live With Remarkable Results
11. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... during and after being treated with post-surgical chemotherapy did not ... from it, according to researchers at Dana-Farber Cancer Institute. ... characterized as cancer in the large bowel area with ... the researchers found that while multivitamin use had no beneficial ...
... of smoking cessation treatments are currently available for the ... smoking each year, but success rates vary widely. Despite ... smoking cessation treatment are needed to help smokers pick ... A major new personalized medicine clinical trial, led by ...
... an intense network of collaborative research. Building on a tool ... recent issue of Brain , Dr. Yaniv Assaf of ... international team of scientists to understand how different parts of ... into a "brain atlas." Brain researchers already know that ...
... disease deaths and hospital admissions, particularly among people from ... Journal of Epidemiology and Community Health . Current ... has improved the overall quality of primary care in ... evidence to suggest that better quality primary care actually ...
... on conserving the use of antibacterial drugs, or face ... antibiotic-resistant infections, according to an analysis out today. ... being depleted by resistance, which occurs when infection-causing microbes ... to widely-used treatments. Most proposals to solve this problem ...
... of California, San Diego School of Medicine have shown ... examining dynamic geometric patterns than they do looking at ... either typical or developmentally delayed toddlers. The results ... patterns early in life may be a signature behavior ...
Cached Medicine News:Health News:Multivitamin use doesn't impact colon cancer outcomes 2Health News:Penn receives $12 million NIH grant to research personalized approach to smoking cessation 2Health News:Mapping a brain atlas 2Health News:Primary care financial incentives cut heart disease deaths and admissions 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Visual pattern preference may be indicator of autism in toddlers 2Health News:Visual pattern preference may be indicator of autism in toddlers 3
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... June 28 Ortho-McNeil-Janssen Pharmaceuticals, Inc. ... agreement with the David H. Koch Institute for ... of Technology .  Called TRANSCEND, the collaboration agreement ... the areas of cancer diagnostics, cancer biology pre-malignancies, ...
... 28 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... Index on June 25, 2010 , when Russell Investments reconstituted its ... , ... on a national exchange, is consistent with our goal of increasing awareness ...
Cached Medicine Technology:Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT 2ADVENTRX Added to Russell Microcap Index 2
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish....
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Medicine Products: